Compare Norfolk Southern Corporation (NSC) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs BIO-TECHNE Corp — how do they compare? Norfolk Southern Corporation trades at $334.8 (market cap $75.01B), while BIO-TECHNE Corp trades at $72.18 (market cap $11.24B). The key difference: Norfolk Southern Corporation is far larger — about 6.7× BIO-TECHNE Corp's market cap, and Norfolk Southern Corporation pays the higher dividend (1.62%). Which is the better fit depends on your goals.
| NSC | TECH | |
|---|---|---|
Market Cap | $75.01B | $11.24B |
Sector | Technology | Health |
52-Week High | $350.66 | $72.29 |
52-Week Low | $272.35 | $43.31 |
Enterprise Value | $90.55B | $11.32B |
Dividend Yield | 1.62% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $334.36, down 2.37% today, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals, including a 21.02% net income margin and consistent earnings beats, with Q2 2026 EPS of $3.52 exceeding expectations. Recent news highlights a potential merger with Union Pacific, adding to positive sentiment amid record revenue growth.
Outlook remains favorable due to operational strength and merger prospects, but risks include high valuation (P/E 28.49) and industry headwinds like fuel costs. Analysts are mixed, with a consensus price target of $369.67, suggesting moderate upside potential from current levels.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
